New Facets of Hematolymphoid Eponymic Diseases

Disease eponyms could be confusing, difficult to remember, scientifically non-robust; lacking implications on and relationship with cell lineage, histogenesis and pathogenesis. This review is geared for revisiting hematolymphoid diseases with eponyms in the light of recent advances in technology and science, by searching the literature using Scopus and Google Scholar with the keywords “eponyms, hematolymphoid, diseases, lymphoma, benign, malignant, lymph node, spleen, liver, bone marrow, leukemia” for the past fifty years. With advances in science and technology, there is accumulation of information on the morphologic nuances, immunologic, immunophenotypic and genetic features of various hematolymphoid eponymic diseases; thus shedding light on important issues of etiology and pathogenesis with implications on therapy in various non-neoplastic (Castleman, Kikuchi-Fujimoto, IgG4-related diseases) and neoplastic (Hodgkin, Burkitt, NK/T-cell lymphomas, dendritic/histiocytic neoplasms and Sezary syndrome) diseases. This contributes to modern nomenclature, classification, subtyping, prognostication and discoveries on new treatment strategies of hematolymphoid eponymic diseases.